Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: Meta-analysis of randomized clinical studies

HIV Clinical Trials

Volumn 15, Issue 6, 2014, Pages 231-245

  Winston, Jonathan ^a   Chonchol, Michel ^b   Gallant, Joel ^c   Durr, Jacques ^d   Canada, Robert B ^e   Liu, Hui ^f   Martin, Patty ^f   Patel, Kiran ^f   Hindman, Jason ^f   Piontkowsky, David ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c Southwest CARE Center   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

adverse events; discontinuation; human immunodeficiency virus; renal toxicity; tenofovir disoproxil fumarate

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR DISOPROXIL; ADENINE; PHOSPHONIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; ARTICLE; ATTRIBUTABLE RISK; DEMOGRAPHY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; MEDLINE; META ANALYSIS; NEPHROTOXICITY; PATIENT SELECTION; PEER REVIEW; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG ADMINISTRATION; HIV INFECTIONS; KIDNEY DISEASE; RISK FACTOR;

ADENINE; ADULT; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; ORGANOPHOSPHONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84916221171     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1506-231     Document Type: Article

References (57)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines.
2. Gilead Sciences Inc. Q4 2013 earnings results: Conference call and Web cast. phx.corporate-ir.net/External. File ?item=UGFyZW50SUQ9MjE4ODUxfENoaWxkSUQ9L TF8VHlwZT0z&t=1. Accessed March 24, 2014.
3. VIREAD (tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.
4. Cooper RD, Wiebe N, et al. Systematic review and metaanalysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
5. Scherzer R, Estrella M, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867-875.
6. Winston J, Deray G, et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47(11): 1449-1457.
7. Mocroft A, Kirk O, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667-1678.
8. Flandre P, Pugliese P, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700-1707.
9. Emerson J, Hoaglin D, et al. A modified random-effect procedure for combining risk difference in sets of 2x2 tables from clinical trials. J Ital Statist Soc. 1993;3:269-290.
10. Emerson J, Hoaglin D, et al. Simple robust procedures for combining risk differences in sets of 2.2 tables. Stat Med. 1996;15:1465-1488.
11. Molina JM, Podsadecki TJ, et al. A lopinavir/ritonavirbased once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23(12):1505-1514.
12. Elion R, Cohen C, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral- naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9(4):213-224.
13. Ortiz R, Dejesus E, et al. Efficacy and safety of oncedaily darunavir/ritonavir versus lopinavir/ritonavir in treatment- naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-1397.
14. Smith KY, Weinberg WG, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.
15. Gathe J, da Silva BA, et al. A once-daily lopinavir/ritonavirbased regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviralnaive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50(5):474-481.
16. Lennox JL, DeJesus E, et al. Safety and efficacy of raltegravir- based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796-806.
17. Mills AM, Nelson M, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679-1688.
18. Walmsley S, Avihingsanon A, et al. Gemini: A noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50(4):367-374.
19. Molina JM, Andrade-Villanueva J, et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV- 1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-332.
20. Post FA, Moyle GJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49-57.
21. Cohen C, Elion R, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25(6):F7-12.
22. Cohen CJ, Andrade-Villanueva J, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, noninferiority trial. Lancet. 2011;378(9787):229-237.
23. Eron JJ Jr, Rockstroh JK, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11(12):907-915.
24. Molina JM, Cahn P, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
25. Soriano V, Arasteh K, et al. Nevirapine versus atazanavir/ ritonavir, each combined with tenofovir disoproxil fumarate/ emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial. Antivir Ther. 2011;16(3):339-348.
26. DeJesus E, Rockstroh JK, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438.
27. Gallant JE, Koenig E, et al. Cobicistat vs ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir disoproxil fumarate/emtricitabine: Phase 3 randomized, double blind, active-controlled trial, week 48 results. Presented at: XIX International AIDS Conference; July 22-27, 2012; Washington, DC.
28. Sax PE, DeJesus E, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448.
29. Cohen CJ, Molina JM, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. AIDS. 2013;27(6):939-950.
30. Orkin C, DeJesus E, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49-59.
31. Rockstroh JK, DeJesus E, et al. A randomized, doubleblind comparison of coformulated elvitegravir/cobicistat/ emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483-486.
32. Rockstroh JK, DeJesus E, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77-85.
33. Zolopa A, Sax PE, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96-100.
34. Gallant JE, Staszewski S, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients: A 3-year randomized trial. JAMA. 2004;292(2):191-201.
35. Gallant JE, DeJesus E, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
36. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV- 1-infected patients. HIV Clin Trials. 2007;8(3):164-172.
37. Arribas JR, Pozniak AL, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/ lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74-78.
38. Sax PE, Tierney C, et al. Supplement to: Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-2240.
39. Smith KY, Patel P, et al. Randomized, double-blind, placebo- matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547-1556.
40. Daar ES, Tierney C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456.
41. Sax PE, Tierney C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J Infect Dis. 2011;204(8):1191-1201.
42. Sax PE, Tierney C, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240.
43. Jones R, Stebbing J, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489-1495.
44. Nelson MR, Katlama C, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS. 2007;21(10):1273-1281.
45. World Health Organization. HIV/AIDS treatment and care. Clinical protocols for the WHO European Region. http://www.euro.who.int/-data/assets/pdf-file/0004/78106/E90840.pdf.
46. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. http://www.who.int/hiv/pub/arv/adult2010/en/index.html.
47. Lepist EI, Phan TK, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409-5413.
48. Lepist EI, Zhang X, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat [published online ahead of print March 19, 2014). Kidney Int.
49. Lazzarin A, Johnson M, et al. 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/ emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). J Int AIDS Soc. 2010;13(Suppl 4):P6.
50. Kalayjian RC, Lau B, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907-1915.
51. Atta MG, Fine DM. Editorial comment: Tenofovir nephrotoxicity - The disconnect between clinical trials and realworld practice. AIDS Read. 2009;19(3):118-119.
52. Furuya-Kanamori L, Kelly MD, et al. Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: A quantitative analysis. PLoS One. 2013;8(10):e78403.
53. Hardy D, Ruane P, et al. Analysis of EVG/COBI/FTC/TDF compared to EFV/FTC/TDF by race in treatment naïve patients [poster 1351]. ID Week (Infectious Diseases Society of America); October 17-21, 2012; San Diego, CA.
54. Gallant JE, Koenig E, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results. J Infect Dis. 2013;208(1):32-39.
55. Ryom L, Mocroft A, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis. 2013;207(9):1359-1369.
56. Elion R, Cohen C, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15):1881-1886.
57. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55-68.